Vertex Pharmaceuticals reported $12.6B of revenue over the trailing twelve months, +10% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $12.6B (to Q2 2026). Net income: $4.41B, trailing twelve months to Q2 2026. Free cash flow: $3.80B, trailing twelve months to Q2 2026. Operating margin: 38%, trailing twelve months to Q2 2026.

VRTXVertex Pharmaceuticals

Healthcare

$510.18+32% 1Y

$510.18

$376.6252 weeks$558.12

VRTX as reported

Vertex Pharmaceuticals reported $12.6B of revenue over the trailing twelve months, +10% on the year before. 11 reported series are charted on this page, each one as filed.

$12.6B

Revenue, trailing twelve months · to Q2 2026 · +10% against the twelve months before

Net income: $4.41B
Net income · +21% year on year · trailing twelve months to Q2 2026
Free cash flow: $3.80B
Free cash flow · +8.5% year on year · trailing twelve months to Q2 2026
Operating margin: 38%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for VRTX, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$12.6B	+10%	Q2 2026
Net income	$4.41B	+21%	Q2 2026
EPS	$17.17	+22%	Q2 2026
Gross margin	86%	n/a	Q2 2026
Operating margin	38%	n/a	Q2 2026
Net margin	35%	n/a	Q2 2026
ROE	22%	n/a	Q2 2026
ROA	16%	n/a	Q2 2026
ROIC	2582%	n/a	Q4 2017 · 34 quarters behind
Free cash flow	$3.80B	+8.5%	Q2 2026
P/E	29.7	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.